Literature DB >> 3327674

Aspects on the benefit-risk balance of felodipine in hypertension.

D Elmfeldt1, S Westerling.   

Abstract

This review attempts to evaluate the benefit-risk balance of felodipine in the treatment of hypertension. Known positive and negative properties of felodipine are considered. Although accurate benefit-risk statements may be difficult even for old, well-established drugs it is concluded that felodipine appears to be an effective and well tolerated new antihypertensive drug. The reduction in blood pressure during felodipine treatment has been superior to that seen with established antihypertensive drugs in controlled studies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3327674     DOI: 10.2165/00003495-198700343-00028

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  14 in total

1.  Microvascular mechanisms involved in calcium antagonist edema formation.

Authors:  D Gustafsson
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

2.  Felodipine as a replacement for minoxidil in the treatment of severe hypertension.

Authors:  C G Wathen; D MacLeod; L Tucker; A L Muir
Journal:  Eur Heart J       Date:  1986-10       Impact factor: 29.983

3.  Gingival hyperplasia associated with nifedipine therapy. Report of a case.

Authors:  D Lederman; H Lumerman; S Reuben; P D Freedman
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1984-06

4.  Acute diuretic/natriuretic properties of felodipine in man.

Authors:  B Edgar; B Bengtsson; D Elmfeldt; P Lundborg; G Nyberg; S Raner; O Rönn
Journal:  Drugs       Date:  1985       Impact factor: 9.546

5.  Vascular selectivity of felodipine.

Authors:  B Ljung
Journal:  Drugs       Date:  1985       Impact factor: 9.546

6.  Effects of felodipine on resistance and capacitance vessels in patients with essential hypertension.

Authors:  A L Muir; C G Wathen; W J Hannan
Journal:  Drugs       Date:  1985       Impact factor: 9.546

7.  Gingival hyperplasia by nifedipine. Report of a case.

Authors:  P L Bencini; C Crosti; F Sala; G Montagnino; A Tarantino; S Menni; R Piccinno
Journal:  Acta Derm Venereol       Date:  1985       Impact factor: 4.437

8.  Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study.

Authors:  B Jackson; T O Morgan; J Gibson; A Anderson
Journal:  Drugs       Date:  1987       Impact factor: 9.546

9.  Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease.

Authors:  W Culling; M S Ruttley; D J Sheridan
Journal:  Br Heart J       Date:  1984-10

10.  Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. Cooperative Study Group.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

View more
  7 in total

1.  Aspects of quality of life on treatment with felodipine.

Authors:  E Dimenäs; M A Wallander; K Svärdsudd; I Wiklund
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Evaluation of three methods of symptom reporting in a clinical trial of felodipine.

Authors:  M A Wallander; E Dimenäs; K Svärdsudd; I Wiklund
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension.

Authors:  C Porcellati; P Verdecchia; C Gatteschi; G Benemio; M Guerrieri; F Boldrini; G Pollavini
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

5.  Felodipine in combination with a beta-adrenoceptor blocker as an effective substitute for triple therapy in severe hypertension. The Australian Felodipine Multicentre Study Group.

Authors:  D B Frewin; P Aldons; L L Wilson; E F O'Sullivan; R N Wyndham; J Karrasch; J Agar; B B Singh; B Jackson; P F Atkins
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Adverse event monitoring in clinical trials of felodipine and omeprazole.

Authors:  M A Wallander; P Lundborg; K Svärdsudd
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Attenuation of renal ischaemic injury by felodipine.

Authors:  P G Thalén; M I Nordlander; M E Sohtell; L E Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-04       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.